Sun Pharmaceutical Industries announced that the US FDA has placed the IND on partial clinical hold for its Deuruxolitinib (CTP-543) due to potential thrombotic events at the 12 mg BID dose in one of the long-term Open Label Extension (OLE) studies, requiring the subjects currently on the 12 mg BID dose in the OLE studies to discontinue that dose.